95198-66-6

Basic information

• Product Name: 3-Pyrrolidinemethanol, 1-(phenylmethyl)-, methanesulfonate (ester)
• CAS NO: 95198-66-6
• Molecular Formula: C13H19NO3S
• Molecular Weight: 269.365
• Mol File: 95198-66-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-Pyrrolidinemethanol, 1-(phenylmethyl)-, methanesulfonate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyrrolidinemethanol, 1-(phenylmethyl)-, methanesulfonate (ester)(95198-66-6)
• EPA Substance Registry System: 3-Pyrrolidinemethanol, 1-(phenylmethyl)-, methanesulfonate (ester)(95198-66-6)

Safety Data

• Hazardous Substances Data: 95198-66-6(Hazardous Substances Data)

Upstream product

• 5731-17-9 1-(Phenylmethyl)-3-pyrrolidinemethanol 
• 540-67-0 ethyl methyl ether 
• 98-59-9 p-toluenesulfonyl chloride 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 874218-13-0 (R/S)-4-(1-benzyl-pyrrolidin-3-ylmethoxy)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

Rifamycin derivatives

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment

A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: STR1 wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH2 -- or STR2 n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the α carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.